Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny
Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a variety of malignancies. However, these responses are frequently short-lived, and patients typically relapse within several months. This phen...
Saved in:
| Published in | Nature communications Vol. 16; no. 1; pp. 5599 - 14 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.07.2025
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a variety of malignancies. However, these responses are frequently short-lived, and patients typically relapse within several months. This phenomenon is largely due to poor persistence of the transgenic T cells, as well as a progressive loss of their functionality and terminal differentiation in vivo. This underscores the need for cell therapy approaches able to sustain the initial antitumor efficacy and lead to long-term antitumor efficacy. Herein, we report the use of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR for the treatment of solid tumors in a first-in-human phase I clinical trial (NCT03240861). This therapy is shown to be safe, feasible, and leads to initial tumor regression activity. T cell progeny from the HSC progenitors is shown to provide circulating transgenic NY-ESO-1 TCR-T cells, which display tumor-antigen-specific antitumor functionality, without any evidence of anergy or exhaustion. These results demonstrate the utility of transgenic HSCs to generate a self-renewing source of tumor-specific cellular immunotherapy in human participants. Clinicaltrials.gov: NCT NCT03240861
Therapeutic T cells engineered to recognize tumour antigens are frequently short-lived and acquire unfavourable phenotypes in tumours. Here authors show that a tandem approach using autologous T cells targeted against the tumour antigen NY-ESO-1, followed by transfer of hematopoietic stem cells with the same specificity in the clinical trial NCT03240861, provides a safe and promising therapeutic option. |
|---|---|
| AbstractList | Abstract Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a variety of malignancies. However, these responses are frequently short-lived, and patients typically relapse within several months. This phenomenon is largely due to poor persistence of the transgenic T cells, as well as a progressive loss of their functionality and terminal differentiation in vivo. This underscores the need for cell therapy approaches able to sustain the initial antitumor efficacy and lead to long-term antitumor efficacy. Herein, we report the use of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR for the treatment of solid tumors in a first-in-human phase I clinical trial (NCT03240861). This therapy is shown to be safe, feasible, and leads to initial tumor regression activity. T cell progeny from the HSC progenitors is shown to provide circulating transgenic NY-ESO-1 TCR-T cells, which display tumor-antigen-specific antitumor functionality, without any evidence of anergy or exhaustion. These results demonstrate the utility of transgenic HSCs to generate a self-renewing source of tumor-specific cellular immunotherapy in human participants. Clinicaltrials.gov: NCT NCT03240861 Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a variety of malignancies. However, these responses are frequently short-lived, and patients typically relapse within several months. This phenomenon is largely due to poor persistence of the transgenic T cells, as well as a progressive loss of their functionality and terminal differentiation in vivo. This underscores the need for cell therapy approaches able to sustain the initial antitumor efficacy and lead to long-term antitumor efficacy. Herein, we report the use of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR for the treatment of solid tumors in a first-in-human phase I clinical trial (NCT03240861). This therapy is shown to be safe, feasible, and leads to initial tumor regression activity. T cell progeny from the HSC progenitors is shown to provide circulating transgenic NY-ESO-1 TCR-T cells, which display tumor-antigen-specific antitumor functionality, without any evidence of anergy or exhaustion. These results demonstrate the utility of transgenic HSCs to generate a self-renewing source of tumor-specific cellular immunotherapy in human participants. Clinicaltrials.gov: NCT NCT03240861Therapeutic T cells engineered to recognize tumour antigens are frequently short-lived and acquire unfavourable phenotypes in tumours. Here authors show that a tandem approach using autologous T cells targeted against the tumour antigen NY-ESO-1, followed by transfer of hematopoietic stem cells with the same specificity in the clinical trial NCT03240861, provides a safe and promising therapeutic option. Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a variety of malignancies. However, these responses are frequently short-lived, and patients typically relapse within several months. This phenomenon is largely due to poor persistence of the transgenic T cells, as well as a progressive loss of their functionality and terminal differentiation in vivo. This underscores the need for cell therapy approaches able to sustain the initial antitumor efficacy and lead to long-term antitumor efficacy. Herein, we report the use of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR for the treatment of solid tumors in a first-in-human phase I clinical trial (NCT03240861). This therapy is shown to be safe, feasible, and leads to initial tumor regression activity. T cell progeny from the HSC progenitors is shown to provide circulating transgenic NY-ESO-1 TCR-T cells, which display tumor-antigen-specific antitumor functionality, without any evidence of anergy or exhaustion. These results demonstrate the utility of transgenic HSCs to generate a self-renewing source of tumor-specific cellular immunotherapy in human participants. Clinicaltrials.gov: NCT NCT03240861. Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a variety of malignancies. However, these responses are frequently short-lived, and patients typically relapse within several months. This phenomenon is largely due to poor persistence of the transgenic T cells, as well as a progressive loss of their functionality and terminal differentiation in vivo. This underscores the need for cell therapy approaches able to sustain the initial antitumor efficacy and lead to long-term antitumor efficacy. Herein, we report the use of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR for the treatment of solid tumors in a first-in-human phase I clinical trial (NCT03240861). This therapy is shown to be safe, feasible, and leads to initial tumor regression activity. T cell progeny from the HSC progenitors is shown to provide circulating transgenic NY-ESO-1 TCR-T cells, which display tumor-antigen-specific antitumor functionality, without any evidence of anergy or exhaustion. These results demonstrate the utility of transgenic HSCs to generate a self-renewing source of tumor-specific cellular immunotherapy in human participants. Clinicaltrials.gov: NCT NCT03240861 Therapeutic T cells engineered to recognize tumour antigens are frequently short-lived and acquire unfavourable phenotypes in tumours. Here authors show that a tandem approach using autologous T cells targeted against the tumour antigen NY-ESO-1, followed by transfer of hematopoietic stem cells with the same specificity in the clinical trial NCT03240861, provides a safe and promising therapeutic option. Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a variety of malignancies. However, these responses are frequently short-lived, and patients typically relapse within several months. This phenomenon is largely due to poor persistence of the transgenic T cells, as well as a progressive loss of their functionality and terminal differentiation in vivo. This underscores the need for cell therapy approaches able to sustain the initial antitumor efficacy and lead to long-term antitumor efficacy. Herein, we report the use of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR for the treatment of solid tumors in a first-in-human phase I clinical trial (NCT03240861). This therapy is shown to be safe, feasible, and leads to initial tumor regression activity. T cell progeny from the HSC progenitors is shown to provide circulating transgenic NY-ESO-1 TCR-T cells, which display tumor-antigen-specific antitumor functionality, without any evidence of anergy or exhaustion. These results demonstrate the utility of transgenic HSCs to generate a self-renewing source of tumor-specific cellular immunotherapy in human participants. Clinicaltrials.gov: NCT NCT03240861 Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a variety of malignancies. However, these responses are frequently short-lived, and patients typically relapse within several months. This phenomenon is largely due to poor persistence of the transgenic T cells, as well as a progressive loss of their functionality and terminal differentiation in vivo. This underscores the need for cell therapy approaches able to sustain the initial antitumor efficacy and lead to long-term antitumor efficacy. Herein, we report the use of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR for the treatment of solid tumors in a first-in-human phase I clinical trial (NCT03240861). This therapy is shown to be safe, feasible, and leads to initial tumor regression activity. T cell progeny from the HSC progenitors is shown to provide circulating transgenic NY-ESO-1 TCR-T cells, which display tumor-antigen-specific antitumor functionality, without any evidence of anergy or exhaustion. These results demonstrate the utility of transgenic HSCs to generate a self-renewing source of tumor-specific cellular immunotherapy in human participants. Clinicaltrials.gov: NCT NCT03240861.Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a variety of malignancies. However, these responses are frequently short-lived, and patients typically relapse within several months. This phenomenon is largely due to poor persistence of the transgenic T cells, as well as a progressive loss of their functionality and terminal differentiation in vivo. This underscores the need for cell therapy approaches able to sustain the initial antitumor efficacy and lead to long-term antitumor efficacy. Herein, we report the use of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR for the treatment of solid tumors in a first-in-human phase I clinical trial (NCT03240861). This therapy is shown to be safe, feasible, and leads to initial tumor regression activity. T cell progeny from the HSC progenitors is shown to provide circulating transgenic NY-ESO-1 TCR-T cells, which display tumor-antigen-specific antitumor functionality, without any evidence of anergy or exhaustion. These results demonstrate the utility of transgenic HSCs to generate a self-renewing source of tumor-specific cellular immunotherapy in human participants. Clinicaltrials.gov: NCT NCT03240861. |
| ArticleNumber | 5599 |
| Author | Rodriguez, Jonathan Klomhaus, Alexandra M. Berent-Maoz, Beata Carretero, Ignacio Baselga Pang, Jia Medina, Egmidio Puig-Saus, Cristina Vega-Crespo, Agustin Peters, Cole W. Ribas, Antoni Kawakami, Moe Allen-Auerbach, Martin Federman, Noah Witte, Owen N. Kidd, Conner K. Comin-Anduix, Begoña Kohn, Donald B. Baltimore, David Garcilazo, Ivan Perez Deen, Nataly Naser Al Schiller, Gary M. Zack, Jerome Nowicki, Theodore S. Champhekar, Ameya Singh, Arun Carlucci, Giuseppe Larson, Sarah J. Chen, Daniel Haile, Salem Chmielowski, Bartosz Macabali, Mignonette H. Yang, Lili Kaplan-Lefko, Paula |
| Author_xml | – sequence: 1 givenname: Theodore S. orcidid: 0000-0002-3815-6137 surname: Nowicki fullname: Nowicki, Theodore S. email: tnowicki@mednet.ucla.edu organization: Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Molecular Biology Institute, University of California Los Angeles, David Geffen School of Medicine, University of California Los Angeles – sequence: 2 givenname: Nataly Naser Al surname: Deen fullname: Deen, Nataly Naser Al organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 3 givenname: Cole W. orcidid: 0000-0001-7052-1432 surname: Peters fullname: Peters, Cole W. organization: Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles – sequence: 4 givenname: Begoña surname: Comin-Anduix fullname: Comin-Anduix, Begoña organization: Jonsson Comprehensive Cancer Center, University of California Los Angeles, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Division of Surgical Oncology, Department of Surgery, University of California Los Angeles – sequence: 5 givenname: Egmidio orcidid: 0000-0002-3284-5329 surname: Medina fullname: Medina, Egmidio organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 6 givenname: Cristina orcidid: 0000-0002-3014-3649 surname: Puig-Saus fullname: Puig-Saus, Cristina organization: Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Parker Institute for Cancer Immunotherapy, UCLA – sequence: 7 givenname: Ignacio Baselga surname: Carretero fullname: Carretero, Ignacio Baselga organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 8 givenname: Paula surname: Kaplan-Lefko fullname: Kaplan-Lefko, Paula organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 9 givenname: Mignonette H. orcidid: 0009-0007-9861-7234 surname: Macabali fullname: Macabali, Mignonette H. organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 10 givenname: Ivan Perez surname: Garcilazo fullname: Garcilazo, Ivan Perez organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 11 givenname: Daniel orcidid: 0000-0001-6660-6257 surname: Chen fullname: Chen, Daniel organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 12 givenname: Jia surname: Pang fullname: Pang, Jia organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 13 givenname: Beata surname: Berent-Maoz fullname: Berent-Maoz, Beata organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 14 givenname: Salem surname: Haile fullname: Haile, Salem organization: Jonsson Comprehensive Cancer Center, University of California Los Angeles, David Geffen School of Medicine, University of California Los Angeles, Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 15 givenname: Jonathan orcidid: 0000-0003-3201-3407 surname: Rodriguez fullname: Rodriguez, Jonathan organization: David Geffen School of Medicine, University of California Los Angeles – sequence: 16 givenname: Moe orcidid: 0009-0008-6981-8114 surname: Kawakami fullname: Kawakami, Moe organization: Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles – sequence: 17 givenname: Conner K. orcidid: 0000-0002-0152-2877 surname: Kidd fullname: Kidd, Conner K. organization: Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles – sequence: 18 givenname: Ameya surname: Champhekar fullname: Champhekar, Ameya organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 19 givenname: Giuseppe surname: Carlucci fullname: Carlucci, Giuseppe organization: Department of Molecular and Medical Pharmacology, University of California Los Angeles – sequence: 20 givenname: Agustin surname: Vega-Crespo fullname: Vega-Crespo, Agustin organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 21 givenname: Bartosz orcidid: 0000-0002-2374-3320 surname: Chmielowski fullname: Chmielowski, Bartosz organization: Jonsson Comprehensive Cancer Center, University of California Los Angeles, Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 22 givenname: Arun surname: Singh fullname: Singh, Arun organization: Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 23 givenname: Noah surname: Federman fullname: Federman, Noah organization: Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, David Geffen School of Medicine, University of California Los Angeles, Department of Orthopaedic Surgery, University of California Los Angeles – sequence: 24 givenname: Gary M. orcidid: 0000-0002-7508-3467 surname: Schiller fullname: Schiller, Gary M. organization: Jonsson Comprehensive Cancer Center, University of California Los Angeles, Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 25 givenname: Sarah J. surname: Larson fullname: Larson, Sarah J. organization: Jonsson Comprehensive Cancer Center, University of California Los Angeles, Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 26 givenname: Martin surname: Allen-Auerbach fullname: Allen-Auerbach, Martin organization: David Geffen School of Medicine, University of California Los Angeles, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles – sequence: 27 givenname: Alexandra M. orcidid: 0000-0002-7676-3595 surname: Klomhaus fullname: Klomhaus, Alexandra M. organization: Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles – sequence: 28 givenname: Jerome surname: Zack fullname: Zack, Jerome organization: Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles – sequence: 29 givenname: David orcidid: 0000-0001-8723-8190 surname: Baltimore fullname: Baltimore, David organization: Division of Biology and Biological Engineering, California Institute of Technology – sequence: 30 givenname: Lili surname: Yang fullname: Yang, Lili organization: Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Molecular Biology Institute, University of California Los Angeles – sequence: 31 givenname: Donald B. orcidid: 0000-0003-1840-6087 surname: Kohn fullname: Kohn, Donald B. organization: Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles – sequence: 32 givenname: Owen N. surname: Witte fullname: Witte, Owen N. organization: Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Molecular Biology Institute, University of California Los Angeles, David Geffen School of Medicine, University of California Los Angeles, Parker Institute for Cancer Immunotherapy, UCLA – sequence: 33 givenname: Antoni orcidid: 0000-0003-3669-8458 surname: Ribas fullname: Ribas, Antoni organization: Jonsson Comprehensive Cancer Center, University of California Los Angeles, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, David Geffen School of Medicine, University of California Los Angeles, Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Parker Institute for Cancer Immunotherapy, UCLA, Department of Molecular and Medical Pharmacology, University of California Los Angeles |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40593578$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1DAQxy1URB_0C3BAkbhwCfiV2DkhVEFbqYgLnC0_xmlWib3YSaXtp8e7KaXlgA9-zW_-nhnPKToKMQBCbwj-QDCTHzMnvBU1pk3dYkna-v4FOqGYk5oIyo6e7I_Rec4bXAbriOT8FTrmuOlYI-QJ-na1TDpUVgcLqZ516mEGVw3TtIRh3lV3g67mpEPuIQy2uoVJz3EbB5jLKc8wVRbGsdqmWIDda_TS6zHD-cN6hn5-_fLj4qq--X55ffH5pra843OZiWsJbb2RXjDXSGGMtk7vE5NScEe8x53xDRhptW8ddw4LLa0vRi4MO0PXq66LeqO2aZh02qmoB3W4iKlXOpUIR1DaGubBMAsEOPa0c0SQrmHACLcOdNH6tGptFzOBsxBKvuMz0eeWMNyqPt4pQinpmKRF4f2DQoq_Fsizmoa8L4sOEJesGKUtaygXrKDv_kE3cUmh1OpAUYmF4IV6-zSkx1j-fFsB6ArYFHNO4B8RgtW-imptD1XaQx3aQ90XJ7Y65QKHHtLft__j9Rttvr76 |
| Cites_doi | 10.1200/JCO.2010.32.2537 10.1038/sj.cgt.7700795 10.1158/1078-0432.CCR-18-0963 10.1038/nm0296-216 10.1146/annurev.med.57.080904.190431 10.1016/S0140-6736(24)00319-2 10.1136/jitc-2023-006930 10.1097/CJI.0000000000000216 10.1016/j.mibio.2004.06.009 10.1182/blood-2005-08-3503 10.1038/s41587-023-01767-y 10.1182/blood-2005-08-024976 10.1186/1479-5876-8-39 10.1038/s41591-020-01225-1 10.1073/pnas.0500600102 10.1016/j.ejca.2008.10.026 10.1016/j.stem.2019.08.004 10.1093/intimm/dxn133 10.1056/NEJMoa2027675 10.1038/nprot.2006.334 10.1007/s00262-008-0461-1 10.1038/mt.2008.5 10.1073/pnas.092154599 10.1155/2018/1948093 10.1371/journal.ppat.1002649 10.1182/blood-2004-02-0414 10.1038/bmt.2012.78 10.1038/nbt1216 10.1007/978-1-59745-409-4_17 10.1038/mt.2015.102 10.1080/21645515.2016.1268745 10.1158/2159-8290.CD-12-0383 10.1074/jbc.M309128200 10.1371/journal.pone.0008208 10.1158/1078-0432.CCR-05-0136 10.1073/pnas.0508698102 10.1073/pnas.0610544104 10.1016/j.cell.2021.04.048 10.1158/0008-5472.CAN-14-0376 10.1038/leu.2008.118 10.1158/1078-0432.CCR-13-3017 10.1089/hum.2006.17.253 10.1038/nprot.2006.459 10.1158/2159-8290.CD-20-0300 10.1038/nm.3910 10.1073/pnas.1115050108 10.1126/science.1118919 10.1158/2159-8290.CD-17-1417 10.1089/hum.2012.202 10.1073/pnas.0337418100 10.1158/1078-0432.CCR-14-2708 10.1158/1078-0432.CCR-18-3496 10.1038/s41591-019-0735-5 10.1038/mt.2013.8 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). Copyright Nature Publishing Group 2025 The Author(s) 2025 2025 |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: Copyright Nature Publishing Group 2025 – notice: The Author(s) 2025 2025 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 SOI 7X8 5PM DOA |
| DOI | 10.1038/s41467-025-60816-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Proquest Medical Database Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2041-1723 |
| EndPage | 14 |
| ExternalDocumentID | oai_doaj_org_article_acb3feb3ce1e40f29d171953e314cdea PMC12219382 40593578 10_1038_s41467_025_60816_z |
| Genre | Journal Article Clinical Trial, Phase I |
| GrantInformation_xml | – fundername: Hyundai Motor Group | Hyundai Motor America | Hyundai Hope On Wheels (Hope On Wheels) funderid: https://doi.org/10.13039/100008258 – fundername: U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) grantid: K08 CA241088; R35 CA197633 funderid: https://doi.org/10.13039/100000054 – fundername: U.S. Department of Health & Human Services | National Institutes of Health (NIH) grantid: UL1TR001881 funderid: https://doi.org/10.13039/100000002 – fundername: California Institute for Regenerative Medicine (CIRM) grantid: CLIN2-11380; INFR4 Alpha Clinic Network Expansion Award funderid: https://doi.org/10.13039/100000900 – fundername: Tower Cancer Research Foundation (TCRF) funderid: https://doi.org/10.13039/100009848 – fundername: U.S. Department of Health & Human Services | National Institutes of Health (NIH) grantid: UL1TR001881 – fundername: California Institute for Regenerative Medicine (CIRM) grantid: CLIN2-11380 – fundername: NCI NIH HHS grantid: R35 CA197633 – fundername: NCATS NIH HHS grantid: UL1 TR001881 – fundername: California Institute for Regenerative Medicine (CIRM) grantid: INFR4 Alpha Clinic Network Expansion Award – fundername: NCI NIH HHS grantid: P30 CA016042 – fundername: NIAID NIH HHS grantid: P30 AI028697 – fundername: NCI NIH HHS grantid: K08 CA241088 |
| GroupedDBID | --- 0R~ 39C 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ AASML ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ADBBV ADFRT ADMLS ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LGEZI LK8 LOTEE M1P M7P M~E NADUK NAO NXXTH O9- OK1 P2P P62 PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP AAYXX CITATION CGR CUY CVF ECM EIF NPM PPXIY PQGLB 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. M48 P64 PJZUB PKEHL PQEST PQUKI PRINS RC3 SOI 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c494t-c41d6126fb8f73d587bbacda10388874d1ff09bf5eb8caf6d4dd07a8cf87447b3 |
| IEDL.DBID | 7X7 |
| ISSN | 2041-1723 |
| IngestDate | Wed Aug 27 01:30:53 EDT 2025 Thu Aug 21 18:33:38 EDT 2025 Tue Aug 26 08:58:18 EDT 2025 Sat Aug 23 12:59:16 EDT 2025 Wed Jul 16 06:55:02 EDT 2025 Thu Jul 03 08:34:38 EDT 2025 Wed Jul 02 02:44:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c494t-c41d6126fb8f73d587bbacda10388874d1ff09bf5eb8caf6d4dd07a8cf87447b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-6660-6257 0000-0002-7676-3595 0000-0002-3014-3649 0000-0001-7052-1432 0000-0002-7508-3467 0000-0002-0152-2877 0000-0003-3201-3407 0000-0002-2374-3320 0009-0007-9861-7234 0000-0002-3815-6137 0000-0002-3284-5329 0000-0003-3669-8458 0000-0001-8723-8190 0000-0003-1840-6087 0009-0008-6981-8114 |
| OpenAccessLink | https://www.proquest.com/docview/3226280774?pq-origsite=%requestingapplication% |
| PMID | 40593578 |
| PQID | 3226280774 |
| PQPubID | 546298 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_acb3feb3ce1e40f29d171953e314cdea pubmedcentral_primary_oai_pubmedcentral_nih_gov_12219382 proquest_miscellaneous_3226352473 proquest_journals_3226280774 pubmed_primary_40593578 crossref_primary_10_1038_s41467_025_60816_z springer_journals_10_1038_s41467_025_60816_z |
| PublicationCentury | 2000 |
| PublicationDate | 2025-07-01 |
| PublicationDateYYYYMMDD | 2025-07-01 |
| PublicationDate_xml | – month: 07 year: 2025 text: 2025-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nature communications |
| PublicationTitleAbbrev | Nat Commun |
| PublicationTitleAlternate | Nat Commun |
| PublicationYear | 2025 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | D Zychlinski (60816_CR33) 2008; 16 DB Kohn (60816_CR28) 2020; 26 J Czernin (60816_CR56) 2006; 57 EP Papapetrou (60816_CR37) 2009; 119 60816_CR12 Y Hao (60816_CR60) 2021; 184 C Puig-Saus (60816_CR14) 2019; 25 SP D’Angelo (60816_CR7) 2018; 8 DN Vatakis (60816_CR9) 2011; 108 C Berger (60816_CR41) 2006; 107 CJ Shu (60816_CR19) 2005; 102 AP Rapoport (60816_CR6) 2015; 21 SS Yaghoubi (60816_CR24) 2006; 1 TS Nowicki (60816_CR8) 2018; 41 WA Weber (60816_CR57) 2005; 46 SS Yaghoubi (60816_CR55) 2006; 1 TS Nowicki (60816_CR36) 2020; 10 E Montini (60816_CR32) 2006; 24 Y Zhu (60816_CR46) 2019; 25 SG Kitchen (60816_CR44) 2012; 8 EA Eisenhauer (60816_CR51) 2009; 45 P Dubey (60816_CR16) 2003; 100 G Brix (60816_CR53) 2005; 46 SS Yaghoubi (60816_CR15) 2005; 12 SN De Oliveira (60816_CR47) 2013; 24 JN Sondergaard (60816_CR58) 2010; 8 CG Radu (60816_CR20) 2007; 104 NB Nagarsheth (60816_CR5) 2021; 27 TS Nowicki (60816_CR3) 2019; 25 S Yaghoubi (60816_CR54) 2001; 42 PF Robbins (60816_CR2) 2015; 21 YJ Kim (60816_CR17) 2004; 6 CJ Shu (60816_CR22) 2009; 21 RM Prins (60816_CR21) 2008; 57 SR Riddell (60816_CR42) 1996; 2 SP D’Angelo (60816_CR26) 2024; 403 U Modlich (60816_CR31) 2008; 22 A Zhen (60816_CR45) 2015; 23 C Baum (60816_CR34) 2006; 17 Y Hao (60816_CR59) 2024; 42 60816_CR38 K Bailey (60816_CR40) 2018; 2018 K Drabko (60816_CR39) 2012; 47 SG Kitchen (60816_CR43) 2009; 4 PF Robbins (60816_CR1) 2011; 29 L Yang (60816_CR11) 2002; 99 EH Gschweng (60816_CR13) 2014; 74 F Giannoni (60816_CR25) 2013; 21 R Figlin (60816_CR49) 1997; 3 L Yang (60816_CR10) 2005; 102 CS Swindle (60816_CR35) 2004; 279 CC Lee (60816_CR18) 2005; 310 DB Kohn (60816_CR29) 2021; 384 U Modlich (60816_CR30) 2006; 108 L Sastry (60816_CR50) 2009; 506 T Chodon (60816_CR4) 2014; 20 C Ma (60816_CR27) 2013; 3 M de Lima (60816_CR23) 2004; 104 B Comin-Anduix (60816_CR52) 2006; 12 SM Larson (60816_CR48) 2017; 13 |
| References_xml | – volume: 29 start-page: 917 year: 2011 ident: 60816_CR1 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.32.2537 – volume: 12 start-page: 329 year: 2005 ident: 60816_CR15 publication-title: Cancer Gene Ther. doi: 10.1038/sj.cgt.7700795 – volume: 25 start-page: 1000 year: 2019 ident: 60816_CR14 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-0963 – volume: 2 start-page: 216 year: 1996 ident: 60816_CR42 publication-title: Nat. Med. doi: 10.1038/nm0296-216 – volume: 57 start-page: 99 year: 2006 ident: 60816_CR56 publication-title: Annu Rev. Med. doi: 10.1146/annurev.med.57.080904.190431 – volume: 403 start-page: 1460 year: 2024 ident: 60816_CR26 publication-title: Lancet doi: 10.1016/S0140-6736(24)00319-2 – ident: 60816_CR38 doi: 10.1136/jitc-2023-006930 – volume: 41 start-page: 248 year: 2018 ident: 60816_CR8 publication-title: J. Immunother. doi: 10.1097/CJI.0000000000000216 – volume: 6 start-page: 331 year: 2004 ident: 60816_CR17 publication-title: Mol. Imaging Biol. doi: 10.1016/j.mibio.2004.06.009 – volume: 119 start-page: 157 year: 2009 ident: 60816_CR37 publication-title: J. Clin. Investig. – volume: 107 start-page: 2294 year: 2006 ident: 60816_CR41 publication-title: Blood doi: 10.1182/blood-2005-08-3503 – volume: 42 start-page: 293 year: 2024 ident: 60816_CR59 publication-title: Nat. Biotechnol. doi: 10.1038/s41587-023-01767-y – volume: 108 start-page: 2545 year: 2006 ident: 60816_CR30 publication-title: Blood doi: 10.1182/blood-2005-08-024976 – volume: 8 year: 2010 ident: 60816_CR58 publication-title: J. Transl. Med. doi: 10.1186/1479-5876-8-39 – volume: 3 start-page: S92 year: 1997 ident: 60816_CR49 publication-title: Cancer J. Sci. Am. – volume: 27 start-page: 419 year: 2021 ident: 60816_CR5 publication-title: Nat. Med. doi: 10.1038/s41591-020-01225-1 – volume: 102 start-page: 4518 year: 2005 ident: 60816_CR10 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0500600102 – volume: 45 start-page: 228 year: 2009 ident: 60816_CR51 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 25 start-page: 542 year: 2019 ident: 60816_CR46 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2019.08.004 – volume: 21 start-page: 155 year: 2009 ident: 60816_CR22 publication-title: Int. Immunol. doi: 10.1093/intimm/dxn133 – volume: 384 start-page: 2002 year: 2021 ident: 60816_CR29 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2027675 – volume: 1 start-page: 2137 year: 2006 ident: 60816_CR55 publication-title: Nat. Protoc. doi: 10.1038/nprot.2006.334 – ident: 60816_CR12 doi: 10.1158/1078-0432.CCR-18-0963 – volume: 57 start-page: 1279 year: 2008 ident: 60816_CR21 publication-title: Cancer Immunol. Immunotherapy CII doi: 10.1007/s00262-008-0461-1 – volume: 16 start-page: 718 year: 2008 ident: 60816_CR33 publication-title: Mol. Ther. doi: 10.1038/mt.2008.5 – volume: 99 start-page: 6204 year: 2002 ident: 60816_CR11 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.092154599 – volume: 2018 year: 2018 ident: 60816_CR40 publication-title: Sarcoma doi: 10.1155/2018/1948093 – volume: 8 start-page: e1002649 year: 2012 ident: 60816_CR44 publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1002649 – volume: 104 start-page: 857 year: 2004 ident: 60816_CR23 publication-title: Blood doi: 10.1182/blood-2004-02-0414 – volume: 47 start-page: 1530 year: 2012 ident: 60816_CR39 publication-title: Bone Marrow Transpl. doi: 10.1038/bmt.2012.78 – volume: 46 start-page: 983 year: 2005 ident: 60816_CR57 publication-title: J. Nucl. Med. – volume: 24 start-page: 687 year: 2006 ident: 60816_CR32 publication-title: Nat. Biotechnol. doi: 10.1038/nbt1216 – volume: 506 start-page: 243 year: 2009 ident: 60816_CR50 publication-title: Methods Mol. Biol. doi: 10.1007/978-1-59745-409-4_17 – volume: 23 start-page: 1358 year: 2015 ident: 60816_CR45 publication-title: Mol. Ther. doi: 10.1038/mt.2015.102 – volume: 13 start-page: 1094 year: 2017 ident: 60816_CR48 publication-title: Hum. Vaccin Immunother. doi: 10.1080/21645515.2016.1268745 – volume: 3 start-page: 418 year: 2013 ident: 60816_CR27 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-12-0383 – volume: 279 start-page: 34 year: 2004 ident: 60816_CR35 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M309128200 – volume: 4 start-page: e8208 year: 2009 ident: 60816_CR43 publication-title: PLoS ONE doi: 10.1371/journal.pone.0008208 – volume: 12 start-page: 107 year: 2006 ident: 60816_CR52 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-05-0136 – volume: 102 start-page: 17412 year: 2005 ident: 60816_CR19 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0508698102 – volume: 104 start-page: 1937 year: 2007 ident: 60816_CR20 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0610544104 – volume: 184 start-page: 3573 year: 2021 ident: 60816_CR60 publication-title: Cell doi: 10.1016/j.cell.2021.04.048 – volume: 74 start-page: 5173 year: 2014 ident: 60816_CR13 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-0376 – volume: 22 start-page: 1519 year: 2008 ident: 60816_CR31 publication-title: Leukemia doi: 10.1038/leu.2008.118 – volume: 42 start-page: 1225 year: 2001 ident: 60816_CR54 publication-title: J. Nucl. Med. – volume: 20 start-page: 2457 year: 2014 ident: 60816_CR4 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-3017 – volume: 17 start-page: 253 year: 2006 ident: 60816_CR34 publication-title: Hum. Gene Ther. doi: 10.1089/hum.2006.17.253 – volume: 1 start-page: 3069 year: 2006 ident: 60816_CR24 publication-title: Nat. Protoc. doi: 10.1038/nprot.2006.459 – volume: 10 start-page: 1645 year: 2020 ident: 60816_CR36 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-20-0300 – volume: 21 start-page: 914 year: 2015 ident: 60816_CR6 publication-title: Nat. Med. doi: 10.1038/nm.3910 – volume: 108 start-page: E1408 year: 2011 ident: 60816_CR9 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1115050108 – volume: 46 start-page: 608 year: 2005 ident: 60816_CR53 publication-title: J. Nucl. Med. – volume: 310 start-page: 1793 year: 2005 ident: 60816_CR18 publication-title: Science doi: 10.1126/science.1118919 – volume: 8 start-page: 944 year: 2018 ident: 60816_CR7 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-1417 – volume: 24 start-page: 824 year: 2013 ident: 60816_CR47 publication-title: Hum. Gene Ther. doi: 10.1089/hum.2012.202 – volume: 100 start-page: 1232 year: 2003 ident: 60816_CR16 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0337418100 – volume: 21 start-page: 1019 year: 2015 ident: 60816_CR2 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-2708 – volume: 25 start-page: 2096 year: 2019 ident: 60816_CR3 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-3496 – volume: 26 start-page: 200 year: 2020 ident: 60816_CR28 publication-title: Nat. Med. doi: 10.1038/s41591-019-0735-5 – volume: 21 start-page: 1044 year: 2013 ident: 60816_CR25 publication-title: Mol. Ther. doi: 10.1038/mt.2013.8 |
| SSID | ssj0000391844 |
| Score | 2.4737256 |
| Snippet | Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a... Abstract Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 5599 |
| SubjectTerms | 13 38/91 42/100 42/44 45 631/250/251 631/532/1542 631/67/1059/2325 692/4028/67/1798 Ablation Adoptive transfer Anergy Anticancer properties Antigen (tumor-associated) Antigens Antigens, Neoplasm - genetics Antigens, Neoplasm - immunology Antitumor activity Bone marrow Cancer therapies Cell therapy Chemotherapy Clinical trials Cytomegalovirus Effectiveness Female Genetic engineering Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Hematopoietic Stem Cells - cytology Hematopoietic Stem Cells - immunology Hematopoietic Stem Cells - metabolism Human subjects Humanities and Social Sciences Humans Immunotherapy Immunotherapy, Adoptive - methods Kinases Lymphocytes Lymphocytes T Male Malignancy Manufacturing Membrane Proteins - genetics Membrane Proteins - immunology Metastasis multidisciplinary Neoplasms - immunology Neoplasms - therapy Patients Phenotypes Progenitor cells Progeny Radiation Receptors, Antigen, T-Cell - genetics Receptors, Antigen, T-Cell - immunology Receptors, Antigen, T-Cell - metabolism Sarcoma Science Science (multidisciplinary) Solid tumors Stem cells T cell receptors T-Lymphocytes - immunology T-Lymphocytes - transplantation Tomography Tumors White people |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5KoNBLaZs-3KZFgd5aE3sl2_IxKQ0hkJwayE3oMaK-eEPiBDa_vjOSd5vtg1568cHSQXyjGX2SRt8AfKwV-r4JVdnZBkslA_lctFh6iU3ARncunXecnbcnF-r0srl8UOqLc8KyPHAG7sB6JyPt-DzWqKq46EPd8dUPylr5gIka0Zr3YDOVYrDsaeui5lcyldQHNyrFBK7e2nKxifJ-ayVKgv1_Ypm_J0v-cmOaFqLjZ_B0ZpDiMI_8OTzC8QU8zjUlV7twlo7lhWdrXpc50RuDGNI7kGkl7gYrJl6gaOYMXiTN1uXVcuDHjIJVnQWf5QvO28Jx9RIujr9--3JSzjUTSq96NdG3DkRa2uh07GRgsJ31wTIGFE9UqGOsehcbdNrb2AYVQtVZ7SPr4HdOvoKdcTniGxCNjq3tvSaOEmgTx_eZlfPEH1BjS0SrgE9r_MxVlsYw6UpbapPRNoS2SWib-wKOGOJNT5a1Tj_I2GY2tvmXsQvYWxvIzL52Yygktazp06kC9jfN5CUMlx1xeZv7ENVUnSzgdbbnZiSKqxpS4CpAb1l6a6jbLePwPSlx1wsK-FIvCvi8nhQ_x_V3LN7-DyzewZMFz-aUOrwHO9P1Lb4ngjS5D8kXfgAWGQ_K priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwEB5RUCUuqKUF0kLlSr21UZPYSZxjuwIhJDgViZvlx7jkkqAlIC2_vh4n2Wpbeuglh8SRRt88PLbH3wB8ygXapnRZWusSU8Fd8DmvMbUcS4elrE3c77i8qs6vxcVNebMFxXwXJhbtR0rLGKbn6rCv9yK6NDVfrahXRPr0AnaIup2selEt1vsqxHguhZjux2RcPvPrxhwUqfqfyy__LpP846w0TkFnr2Bvyh3Zt1Ha17CF3T68HLtJrt7AZdyQZ5b0uEzHEm90rI03QIYVe2w1G2hqCjbTWhbZWvu7vqVrjIz4nBnt4jOq2MJu9Rauz05_LM7TqVtCakUjhvDMXUhXKm-kr7kjmI22ThMGIZIIl3ufNcaXaKTVvnLCuazW0nqCsTb8ALa7vsMjYKX0lW6sDNmJC8s3OsnMjA2ZA0qsQoqVwOcZP3U3kmKoeJjNpRrRVgFtFdFWTwl8J4jXI4nQOr7olz_VpGClreE-LOwt5igyXzQur-mED3kurEOdwPGsIDV52b0KwagiNp9aJPBx_Tn4B8GlO-wfxjEhyRQ1T-Bw1OdaEkH9DEPISkBuaHpD1M0vXXsbObjzIoR6LosEvsxG8Vuuf2Px7v-Gv4fdguw2lgcfw_awfMCTkAQN5kO0-l-KxgQp priority: 102 providerName: Springer Nature |
| Title | Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny |
| URI | https://link.springer.com/article/10.1038/s41467-025-60816-z https://www.ncbi.nlm.nih.gov/pubmed/40593578 https://www.proquest.com/docview/3226280774 https://www.proquest.com/docview/3226352473 https://pubmed.ncbi.nlm.nih.gov/PMC12219382 https://doaj.org/article/acb3feb3ce1e40f29d171953e314cdea |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9swDCa2FgN2Gfaeuy7QgN02o3YsW_JpSINmRYAWw7YCuQmyHpsvdpa4A9JfX1J2UmSviw1YPsgfKYomqY8A71LuTJnbJBY6dzHPLK45r11sMpdbl0tRhXjHxWVxfsXni3wxBNzWQ1nl1iYGQ21bQzHyE1S8gphbBP-4_BlT1yjKrg4tNO7DIVGXUUmXWIhdjIXYzyXnw1mZJJMnax4sA_VwLajlRHyztx8F2v6_-Zp_lkz-ljcN29HsMTwa_Eg26QX_BO655ik86DtLbp7BRQjOM0MyXcV9ubezrA6nQboN-1Vr1tE2hfpTGxaYW9tlW9ORRkbczowi-oyqt1yzeQ5Xs7Nv0_N46JwQG17yDq-pRdel8JX0IrMEeaWN1YQBWhVuU--TsvK5q6TRvrDc2kRoaTyx4YsqewEHTdu4V8By6QtdGomeisVfOcpqJpVBL8JJV6C7FcH7LX5q2RNkqJDYzqTq0VaItgpoq5sITgni3ZtEbh0etKvvalgrSpsq8_iTb1zqeOLHpU0FZftclnJjnY7geCsgNay4tbrTjwje7oZxrRBcunHtdf8OOpxcZBG87OW5mwmn3oZoviKQe5Lem-r-SFP_CHzc6RjNfibHEXzYKsXdvP6NxdH_P-M1PByTnobS4GM46FbX7g06QF01ClqOVzn7NILDyWT-dY7307PLz1_w6bSYjkJo4RYUAgut |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgQXxJtAASPBCaImsZM4B4R4LVva7amVejN-Qi7JspuCtj-K34jHSbZaXrdeckgsyxl_4xl7xt8APEuZ1VVukriUuY0ZNV7nnLSxpjY3NuelCucds8Niesw-neQnW_BzvAuDaZXjmhgWatNqPCPf9cArkLmlZK_n32KsGoXR1bGERg-Lfbv64bdsy1d77_38Ps-yyYejd9N4qCoQa1axzj9T48164RR3JTU4HCW1kcgU7jWOmdS5pFIut4pr6QrDjElKybVDpvhSUd_vJbjMKK1Qo_jk4_pMB9nWOWPD3Rzf3-6ShZUIa8YWWOIiPtuwf6FMwN982z9TNH-L0wbzN7kB1we_lbzpgXYTtmxzC670lSxXt2EWggFEI4YWcZ9ebg2pw-2TbkW-15J0aBY9XmtNAlNsO29rvEJJkEuaYASBYLaYbVZ34PhCZHoXtpu2sfeB5NwVstLce0bGbx0xipoo7b0Wy23h3bsIXozyE_OekEOEQDrlope28NIWQdriLIK3KOJ1SyTTDi_axRcx6KaQWlFnFdU2tSxxWWXSEqOLlqZMGysj2BknSAwavhTneIzg6fqz100Ul2xse9q38Q4uK2kE9_r5XI-EYS1Fv1xGwDdmemOom1-a-mvg_04zb2YozyJ4OYLifFz_lsWD___GE7g6PZodiIO9w_2HcC1DzIa05B3Y7han9pF3vjr1OCCewOeLVrFfmeVEgw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIhAXxLMEChgJThDtJnZi7wEhoKxaSisOVNqbcfyAvSTL7ha0_Wn8OmacZKvldeslh8SynPE3nrFn_A3A00x4OyrcMJWm8KngDnUuGJ9a7gvnCyWreN5xdFzun4j3k2KyBT_7uzCUVtmviXGhdo2lM_IBAq8k5hYpBqFLi_i4N341-5ZSBSmKtPblNFqIHPrVD9y-LV4e7OFcP8vz8btPb_fTrsJAasVILPGZOTTxZahUkNzR0CpjnSHWcNQ-4bIQhqMqFL5S1oTSCeeG0igbiDVeVhz7vQSXJS8y0jE5kevzHWJeV0J093Swv8FCxFWJ6seWVO4iPduwhbFkwN_83D_TNX-L2UZTOL4B1zsflr1uQXcTtnx9C660VS1Xt-EoBgaYJTzN0zbV3Ds2jTdRliv2fWrYkkwkYndqWWSNbWbNlK5TMuKVZhRNYJQ55uvVHTi5EJnehe26qf09YIUKpRlZhV6Sw20kRVSHlUUPxitfoquXwPNefnrWknPoGFTnSrfS1ihtHaWtzxJ4QyJetyRi7fiimX_RnZ5qYysefMWtz7wYhnzkMkmRRs8zYZ03Cez2E6Q7bV_oc2wm8GT9GfWUxGVq35y2bdDZFZInsNPO53okguoq4tKZgNqY6Y2hbn6pp18jF3iWo8nhKk_gRQ-K83H9Wxb3__8bj-EqKpf-cHB8-ACu5QTZmKG8C9vL-al_iH7YsnoUAc_g80Vr2C9j10iw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+cancer-targeted+immunity+via+transgenic+hematopoietic+stem+cell+progeny&rft.jtitle=Nature+communications&rft.au=Nowicki%2C+Theodore+S.&rft.au=Deen%2C+Nataly+Naser+Al&rft.au=Peters%2C+Cole+W.&rft.au=Comin-Anduix%2C+Bego%C3%B1a&rft.date=2025-07-01&rft.issn=2041-1723&rft.eissn=2041-1723&rft.volume=16&rft.issue=1&rft_id=info:doi/10.1038%2Fs41467-025-60816-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41467_025_60816_z |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon |